Insilico and SK Bio Sign $2.5B AI Discovery Deal
Insilico Medicine and SK Biopharmaceuticals signed a collaboration worth up to $2.5 billion to discover neuroimmune drugs with AI.
AI
Alnylam and Inceptive Sign AI siRNA Deal
Alnylam will pay $30 million upfront in a collaboration with Inceptive to improve siRNA design using generative AI.
Concept and OpenBench Launch AI Discovery Deal
Concept Life Sciences and OpenBench partner on success-based AI hit discovery, combining structure-based AI with lab capabilities.
AstraZeneca Expands Immunai AI Partnership
Immunai secured up to $37.5M as AstraZeneca expands use of its AMICA-OS platform in oncology clinical development.
20n Bio Raises $7.5M Seed+ Round
20n Bio raised $7.5 million to expand its cyclic peptide discovery platform and add AI into its discovery workflow.
Benchling and Baseten Bring AI Inference to Biotech R&D
Benchling and Baseten launched Benchling Inference to give biotech teams scalable GPU access for scientific AI models.
Bristol Myers Squibb Deepens AI Push with Anthropic Partnership
Bristol Myers Squibb is partnering with Anthropic to use Claude AI tools to speed drug development and analyse internal data.
Metis TechBio Goes Public with $270M for AI Nanodelivery
Metis TechBio raised $270 million in a Hong Kong Stock Exchange IPO, led by cornerstone investors, to advance AI-designed nanomaterial drug delivery platforms.
Isomorphic Labs Raises $2.1B in Series B
Alphabet-backed Isomorphic Labs secured $2.1 billion to expand AI drug design, grow its team and advance internal programmes.
Sanofi Expands Toronto AI hub with $294M
Sanofi will invest $294M to expand its Toronto AI Centre of Excellence, creating 50 jobs and scaling AI across research, manufacturing and business.